---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

Roche

🌎 roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics, founded in 1896 in Basel, Switzerland. The company focuses on advancing science to improve people's lives, with a strong emphasis on personalized healthcare. Roche is the world's largest biotech company, known for its innovative medicines in oncology, immunology, infectious diseases, and diagnostics. The company aims to improve patient access to medical innovations and has been recognized for its sustainability efforts in the pharmaceuticals and biotechnology industry.

---

Roche - Latest News and Updates

• Roche Tissue Diagnostics developed the FDA-approved VENTANA FOLR1 RxDx assay for assessing folate receptor α expression in certain cancers.
• Roche is hiring a Chief of Staff for Global Safety, Health & Environment in Basel, Switzerland, to drive strategy and collaboration within their Corporate Strategy & Sustainability organization.
• Delhi High Court has asked NATCO Pharma to pause the launch of Risdiplam due to a patent dispute with Roche.
• On March 26, 2025, the University of Liverpool signed a Memorandum of Understanding with Roche Diagnostics UK and Ireland to advance research and innovation for health improvement and community prosperity.
• Roche invested $36 million in Puretech with potential milestone payments and royalties up to $1 billion.

• On March 25, 2025, Roche re-elected Severin Schwan as Chairman of the Board and announced a 38th consecutive dividend increase to CHF 9.70 per share at its Annual General Meeting.
• Roche has partnered with Merck KGaA to commercialize the lung cancer drug Tepmetko in mainland China.
• Belgian anti-trust authorities are investigating Roche for allegedly delaying biosimilars of two cancer medicines by offering financial incentives to hospitals and spreading misleading information.
• Roche is set to enter the pan-RAS inhibitor market with the first-in-human trial of RO7673396, starting April 30, 2025.
• On March 21, the FDA approved Roche's Susvimo as the first continuous treatment for diabetes-related blindness.

---

Sign up to receive regular updates

If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.